Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
11 January 2016 |
Main ID: |
EUCTR2011-000595-33-NL |
Date of registration:
|
19/11/2015 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
Repeated application of bone marrow-derived stem cells to treat chronic
post-infarction heart failure
|
Scientific title:
|
Randomized controlled trial to compare the effects of single versus
repeated intracoronary application of autologous bone marrow-derived
mononuclear cells on total and SHFM-predicted mortality in patients with
chronic post-infarction heart failure
REpetitive Progenitor cEll therapy in Advanced chronic hearT failure
(REPEAT trial) - REPEAT |
Date of first enrolment:
|
17/12/2015 |
Target sample size:
|
676 |
Recruitment status: |
Authorised-recruitment may be ongoing or finished |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2011-000595-33 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: yes
Randomised: yes
Open: yes
Single blind: no
Double blind: no
Parallel group: yes
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: yes
Other specify the comparator: single versus sequentential treatment
Number of treatment arms in the trial: 2
|
Phase:
|
|
|
Countries of recruitment
|
Germany
|
Netherlands
| | | | | | |
Contacts
|
Name:
|
Cardiology
|
Address:
|
Theodor-Stern-Kai 7
60590
Frankfurt
Germany |
Telephone:
|
+4906963015789 |
Email:
|
zeiher@em.uni-frankfurt.de |
Affiliation:
|
Goethe University |
|
Name:
|
Cardiology
|
Address:
|
Theodor-Stern-Kai 7
60590
Frankfurt
Germany |
Telephone:
|
+4906963015789 |
Email:
|
zeiher@em.uni-frankfurt.de |
Affiliation:
|
Goethe University |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: • Previous myocardial infarction at least 3 months ago, open infarct
vessel or bypass
• Left ventricular ejection fraction (LVEF) = 45% on echocardiography
• Stable chronic heart failure NYHA class II to III under constant (4
weeks) evidence-based optimal medical treatment
• age 18 – 80 years
• written informed consent
• women of childbearing age: negative pregnancy test; effective
contraception for the first 8 months in the trial Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 176 F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range 500
Exclusion criteria: • Non-ischemic cardiomyopathy
• Necessity for revascularization in other vessel than the infarct vessel
at the time of study therapy
XML File Identifier: v+I18a18i5BGdxhV1XCe9gTJXBA=
Page 10/20
• Hemodynamic relevant severe valvular disease with indication for
operative / interventional revision
• Heart failure with preserved ejection fraction (diastolic heart failure),
LVEF > 45%
• Unstable Angina
• Severe peripheral artery occlusive disease (= Fontaine stadium III)
• Active infection (C-reactive protein > 10 mg/dl), chronic active
hepatitis; any chronic inflammatory disease, HIV infection
• Neoplastic disease without documented remission in the last 5 years
• Stroke = 3 months
• Impaired renal function (Serum creatinine > 2,5 mg/dl) at the time of
study inclusion
• Relevant liver disease (GOT > 2x upper normal limit, spontaneous
INR > 1,5).
• Diseases of hematopoetic system, anemia (Hemoglobin < 8.5 mg/dl),
thrombocytopenia < 100.000/µl)
• Splenomegaly
• Allergy or intolerance of clopidogrel, prasugrel, ticagrelor, heparin,
bivalirudin
• History of bleeding disorder
• gastrointestinal bleeding = 3 months
• major surgery or trauma = 3 months
• Uncontrolled hypertension
• Pregnancy, lactation period
• mental retardation
• previous cardiac cell therapy within last 12 months
• Participation in another clinical trial = 30 days
Age minimum:
Age maximum:
Gender:
Female: yes Male: yes
|
Health Condition(s) or Problem(s) studied
|
Chronic post-infarction heart failure due to an at least 3 months old myocardial infarction, treated with optimal medication according to the evidence-based guidelines, in NYHA stadium II-III; and with open vessel / bypass sullpying the previously infarcted area
|
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
|
Intervention(s)
|
Product Name: t2c001 Product Code: t2c001 Pharmaceutical Form: Solution for infusion
|
Primary Outcome(s)
|
Main Objective: Improve mortality in patients with symptomatic chronic post-infarction heart failure under full dose conventional medical and device treatment including resynchronization therapy frequently by intracoronary infusion of autologous bone marrow-derived mononuclear cells.
|
Primary end point(s): 2-year observed mortality is significantly lower in patients receiving 2 repeated intracoronary applications of autologous bone marrow-derived cells (t2c001) compared to patients receiving 1 intracoronary application of autologous bone marrow-derived cells (t2c001)
|
Secondary Objective: Improve morbidity in patients with symptomatic chronic post-infarction heart failure under full dose conventional medical and device treatment including resynchronization therapy frequently by intracoronary infusion of autologous bone marrow-derived mononuclear cells.
|
Timepoint(s) of evaluation of this end point: 2 years after inclusion into the trial
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: 2 years after inclusion into the trial
|
Secondary end point(s): Efficacy endpoints:
- In patients receiving 2 repeated intracoronary applications of
autologous bone marrow-derived cells (t2c001), the observed mortality
is significantly lower than the SHFM-predicted mortality at 2-year followup
Comparison between the 2 treatment groups at 2-year follow-up
- Cardiac mortality, cardiovascular mortality
- Rehospitalisation for heart failure
- Ischemic cardiac events (STEMI, NSTEMI, ACS)
- Coronary revascularisations (PCI / CABG)
- Heart transplantation, Assist-device implantation
- New resynchronization therapy, ICD implantation
- NYHA-Status, NT-proBNP serum levels
- Minnesota Living with Heart Failure Questionnaire
Prespecified combined clinical endpoints:
o Death and rehospitalisation for heart failure
o Cardiac Death and rehospitalisation for heart failure
XML File Identifier: v+I18a18i5BGdxhV1XCe9gTJXBA=
Page 11/20
o Cardiac and Cardiovascular Death and rehospitalisation for heart
failure
o Death and myocardial infarction
o Death and myocardial infarction and rehospitalisation for heart failure
o Death and myocardial infarction and revascularization
o Death and any cardiovascular event
Safety endpoints:
- Life-threatening arrhythmias (sustained ventricular tachycardia;
ventricular fibrillation and cardiopulmonary resuscitation)
- Any new malignant disease
- Bleeding events
- Safety of intracoronary application of autologous bone marrow-derived
cells (t2c001) (procedural complications, adverse events at 30 days and
4 months after application, SAEs at 1 and 2 years)
|
Secondary ID(s)
|
2011-000595-33-DE
|
2011-01-01REPEAT
|
Source(s) of Monetary Support
|
Goethe University Frankfurt
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|